Ownership change in Calmark – Creades becomes third largest owner

Ownership change in Calmark – Creades becomes third largest owner

Press releases
Creades AB (publ), a listed investment company with a net asset value of more than SEK 4 billion, have subscribed for and acquired B shares and Series TO 2 B subscription warrants in Calmark Sweden AB (publ) (“Calmark” or the “Company”) corresponding to an amount of MSEK 6.3. These transactions represent 9.44 percent of the Company's shares, which entails that Creades AB (publ) now becomes the third largest shareholder of Calmark.

The transaction has been carried out in two stages, first by subscribing with the support of unit rights corresponding to 611,772 B shares and 203,924 Series TO 2 B subscription warrants in Calmark's rights issue, which was completed on 29 November 2019. The unit rights were transferred from Mathias Karlsson, founder and Chairman of the Board. In addition to this, Creades AB (publ) has acquired paid subscription units (BTU) corresponding to 1,300,608 B shares and 433,536 Series TO 2 B subscription warrants from the main owner Lars Wingefors, through the company Wingefors Invest AB. Creades AB (publ) did not have any ownership in Calmark before the rights issue.

After the transactions, Creades AB (publ) holds 1,912,380 B shares in Calmark, corresponding to 7.61 percent of the votes and 9.44 percent of the share capital. Moreover, Creades AB (publ) holds 637,460 Series TO 2 B subscription warrants in the Company following the transactions. Wingefors Invest AB remains the main owner of the Company, with 22.75 percent of the votes and 22.47 percent of the share capital (from 32.19 percent of the votes and 35.31 percent of the share capital).

“I invested in Calmark at an early stage, since it is a company from Värmland with a global market, a strong team and, above all, a product that really makes a difference for newborns, regardless of where they are born in the world. It matters a lot for any listed company to have recognized, long-term owners; therefore, I am glad that Creades wants to become a new long-term major owner in Calmark. It was clear to me as soon as I received the enquiry that I wanted to facilitate it,” Lars Wingefors says.

“Medtech is a priority area for Creades. Calmark combines a strong product that can make a difference in the care of newborns with a team that is highly experienced in medtech sales and commercialization. The Company is at a very interesting stage, with the CE conformity marking process, product launch and expected first revenue in the forthcoming year; we are really looking forward to following the Company's developments,” says John Hedberg, CEO of Creades.

“We are so happy to welcome Creades to Calmark as a new owner. It is very valuable for the Company to gain another long-term, well-renowned owner, with extensive experience in business development,” says Anna Söderlund, CEO of Calmark.

Financial advisor

Stockholm Corporate Finance has acted as Calmark’s financial adviser in the rights issue.

For more information about Calmark Sweden AB (publ), please contact:

Anna Söderlund, CEO
Telephone: +46 70 213 25 35
E-mail: anna.soderlund@calmark.se

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 4 December 2019, 8:55 CET.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

About Calmark Sweden AB (publ)
Calmark is a medical technology company developing a point-of-care (POC) analysis method with easier and faster sampling of medical conditions in newborns. The unique test platform, which consists of a reader and single-use products, is expected to be ready for launch in 2020 when three important POC tests are introduced. The WHO estimates that 1.5 billion children will be born worldwide by 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter healthcare chains. In less developed healthcare systems, the product helps save lives. Calmark aims to become the global leader and ultimately to offer all relevant POC tests for the newborn's first period of life, wherever they are born. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more about Calmark at www.calmark.se/eng/home.

About Stockholm Corporate Finance
Stockholm Corporate Finance is a Swedish, independent and privately-owned financial advisor offering qualified transaction based advisory services by acting in capital raisings, changes in ownership, acquisition, merger and acquisitions (M&A) in listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network of M&A Worldwide consisting of 42 M&A advisors and investment banks in 43 countries. Stockholm Corporate Finance is an investment firm which is supervised by the FSA and is a member of the trade organization SwedSec Licensing AB. www.stockholmcorp.se